Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common anesthesia drug shield the brain after heart surgery?

NCT ID NCT07759297

Knowledge-focused Sponsor: Shusheng Li Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This observational study looks at whether giving dexmedetomidine during cardiac surgery is linked to a lower chance of postoperative delirium—a state of confusion that can occur after surgery. Researchers will analyze medical records from over 5,000 adults who had heart surgery with a heart-lung machine, comparing those who received the drug with those who did not. They will also test stored blood samples for a protein linked to inflammation to explore a possible biological connection. The goal is to understand if this drug might help protect the brain after major heart surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dexmedetomidine
What this could lead to
If dexmedetomidine is linked to a lower risk of postoperative delirium, it could guide anesthesia choices to protect brain health after cardiac surgery.
What could go wrong
This is an observational study, so it can only show associations, not cause and effect. The drug's use was decided by doctors, not randomly assigned, so other factors may influence the results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5,688 people

The number who actually took part.

Started

Apr 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of adults aged 18 years or older who underwent cardiac surgery with cardiopulmonary bypass. The retrospective cohort included eligible patients treated at three campuses of Tongji Hospital between January 2015 and December 2022. The prospective biomarker cohort consisted of participants enrolled between April 2023 and September 2024 for whom archived perioperative plasma samples and linked clinical data were available.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). * For the retrospective cohort, eligible patients undergoing cardiac surgery with CPB at the three participating campuses of Tongji Hospital between January 2015 and December 2022. * For the prospective biomarker cohort, eligible participants enrolled between April 2023 and September 2024 with archived plasma samples collected preoperatively, at the end of surgery, and 24 h postoperatively, together with linked clinical data. Exclusion Criteria: * Conditions precluding dexmedetomidine use, including second- or third-degree atrioventricular block without a pacemaker, uncontrolled hypotension, acute cerebrovascular disease, or known hypersensitivity to dexmedetomidine. * Severe neurological or psychiatric disorders, including a history of treatment for severe mental illness. * Inability to communicate effectively because of severe hearing, visual, or speech impairments. * Pregnancy or breastfeeding. * Emergency surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative delirium are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Emergence Delirium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postoperative delirium

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.